Since conventional systemic chemotherapy has limited therapeutic efficiency against PDAC, understanding the cancer immune microenvironment, including galectin-9 in PDAC, and exploring its potential as a new therapeutic strategy may improve the prognosis of this deadly disease (Table 1). This evidence concerns the gene LGALS9 and cancer.